

RECEIVED
REGION 1

sanofi pasteur

The vaccines business of sanofi-aventis Group

'05 MAY 12 01:05

J-6
MS-16

11 May 2005

US Nuclear Regulatory Commission
Region 1
475 Allendale Road
King of Prussia, PA 19406
Attn: Thomas K. Thompson

03013723

Re: License renewal, Byproduct Material License Number 37-17938-01,
Response to NRC letter for additional information, Control No. 136526

Dear Mr. Thompson:

This is in response to your letter of April 19, 2005 requesting additional information. The numbers refer to those items in your letter.

1. The company changed its name from Aventis Pasteur to Sanofi Pasteur effective January 14, 2005. Please see attached documentation.
2. There are no changes to the organizational structure or the radiation safety program that relate to the licensed program.
3. The transferee, Sanofi Pasteur, confirms that it will abide by all constraints, conditions, requirements and commitments in the license, the NRC's regulations, and the radiation safety program committed to by the transferor, Aventis Pasteur.
4. We prefer to have the flexibility of being able to move laboratories without the restraint of amending the license, as such, we request not having to specifically describe each room in which radioactive material is used or stored. We believe the low activities, the actual radioactive materials presently being used, and the shielding capabilities of the containers and hoods, and the laboratory construction should allow this flexibility. For example, the typical quantities on hand at any one time are: 2 to 5 millicuries of tritium, 0.05 to 0.1 millicurie of chlorine 36, and 0.1 to 0.2 millicurie of iodine 125. The containers and the hoods in which they are used will prevent exposure outside the hood. With respect to iodine 125, the liquid is stored in a carboy, which is


covered by 10-gauge stainless steel. This will reduce the exposure rate outside the laboratory to non-detectable levels. As such, distance and the normal materials of construction of the rooms provide all the shielding necessary to maintain potential radiation doses to non-occupational workers as low as reasonably achievable. Each laboratory is constructed of plasterboard walls, at least 3/8 inch thick which will provide an additional iodine 125 shielding factor of around 2.7 times. None of the radioactive materials are in a volatile form. The fume hoods are used for biological protection and to maintain uniform temperatures rather than radiological protective devices. At present, there are four rooms being utilized for licensed work involving radioactive materials. One laboratory is used to grow tritium cultures and for iodine activities; all activities take place in fume hoods. A second laboratory is used for the storage of stock solutions, the incubation of tritium cultures and as the analyst's office. All incubation and extraction work in this laboratory is performed in fume hoods and all storage is in the freezer. A third room is used for the analyses in either liquid scintillation counters or in a gamma counter. The fourth room is the waste storage room used to store short-lived waste for decay and as temporary storage awaiting pickup for disposal.

Security in each room in Building is maintained by programmable key card readers, which can be quickly and easily reprogrammed to admit and exclude any worker. The platform leader determines who is permitted to enter a room. This would allow the restriction of access whenever a laboratory is changed.

When a laboratory is changed, we perform a termination survey to demonstrate that no residual contamination exists. This survey is documented. Sanofi Pasteur will notify the NRC of the termination of one laboratory and the beginning of use of another as an informative notification and not as a request for a license amendment. The documentation of laboratory changes will be maintained.

Should there be any questions regarding the administrative aspects of the application, please contact Garvin Bixler, Ph.D. at 570-895-3526. For health physics aspects, you may contact Anthony LaMastra at 610-756-4153.

Sincerely,



Garvin S. Bixler, Jr., Ph.D.
Platform Leader, Immunochemistry
Global Clinical Immunology
NA Analytical Science and Assay Development

UNANIMOUS CONSENT IN LIEU OF
A MEETING OF THE BOARD OF DIRECTORS
OF
AVENTIS PASTEUR INC.

THE UNDERSIGNED, being all the Directors of the above named Corporation, hereby adopt the following Resolutions to the same extent as though such actions had been authorized at a regular meeting of the Board of Directors held pursuant to notice.

WHEREAS, the Corporation desires to change the name of the Corporation, and to do business in the United States of America under the name "Sanofi Pasteur Inc.;" and

WHEREAS, the Corporation has proceeded through its duly authorized officers to effectuate the registration of the name, "Sanofi Pasteur Inc." with the states so requiring registration.

NOW, THEREFORE, be it resolved that the Corporation hereby adopts the following resolutions:

RESOLVED, that the Certificate of Incorporation of Aventis Pasteur Inc. be amended by changing the Article thereof numbered "1." so that, as amended, said Article shall be and read as follows:

"1. The name of the Corporation is Sanofi Pasteur Inc."

RESOLVED, that the proposed and recommended amendment be submitted to the Stockholders of the Corporation, or, be the subject of a Unanimous Consent thereof;

RESOLVED, that at any time prior to the effectiveness of the filing of the amendment with the Secretary of State, notwithstanding authorization of the proposed amendment by the Stockholders of the Corporation, the Board of Directors may abandon such proposed amendment without further action by the Stockholders of Board of Directors;

RESOLVED, that the Corporation, through its duly elected Board of Directors, hereby ratifies as official corporate actions all the name registrations for the name

"Sanofi Pasteur Inc.", heretofore duly prepared and filed with the respective state authorities;

RESOLVED, that the Officers of the Corporation are hereby authorized to take any and all necessary actions to complete the effectuation of the registration of the name "Sanofi Pasteur Inc." with the appropriate state authorities;

RESOLVED, that the effective date of the change of the Corporation's name "Sanofi Pasteur Inc." shall be January 13, 2005 or upon the filing of a Certificate of Amendment of the Certificate of Incorporation with the Secretary of State of the state of Delaware, whichever occurs last;

RESOLVED, that any and all actions heretofore or hereinafter taken and expenses incurred by the officers of the Company in order to effectuate the foregoing resolution are hereby ratified, confirmed, adopted and approved as the act and deeds of the Company;


RESOLVED, that this Unanimous Consent may be executed in one or more counterparts, all of which, taken together, shall constitute but one and the same instrument;

FURTHER RESOLVED, that the Secretary of the Corporation shall file this Unanimous Consent with the minutes of the meetings of the Board of Directors of the Corporation.


AVENTIS PASTEUR INC.



David J. Williams, Director



Damian A. Braga, Director



Wayne F. Pisano, Director

The foregoing Unanimous Consent of the Directors was executed on the 10th day of January, 2005 and filed with the undersigned on the 10th day of January, 2005.



Charles S. Montgomery, Secretary

Delaware

PAGE 1

The First State.

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF "AVENTIS PASTEUR INC.", CHANGING ITS NAME FROM "AVENTIS PASTEUR INC." TO "SANOFI PASTEUR INC.", FILED IN THIS OFFICE ON THE FOURTEENTH DAY OF JANUARY, A.D. 2005, AT 3:33 O'CLOCK P.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.



0833607 8100

050036296

Harriet Smith Windsor

Harriet Smith Windsor, Secretary of State

AUTHENTICATION: 3626963

DATE: 01-19-05

CERTIFICATE OF AMENDMENT
OF
CERTIFICATE OF INCORPORATION
OF
AVENTIS PASTEUR INC.

AVENTIS PASTEUR INC., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY:

FIRST: That the Directors of said corporation, by written consent, filed with the minutes of the board, adopted a resolution proposing and declaring advisable the following amendment to the Certificate of Incorporation of said corporation:

RESOLVED, that the Certificate of Incorporation of Aventis Pasteur Inc. be amended by changing the Article thereof numbered "1." so that, as amended, said Article shall be and read as follows:

"1. The name of the corporation is Sanofi Pasteur Inc."

SECOND: That in lieu of a meeting and vote of stockholders, the stockholders have given unanimous written consent to said amendment in accordance with the provisions of Section 228 of The General Corporation Law of the State of Delaware.

THIRD: That the aforesaid amendment was duly adopted in accordance with the applicable provisions of Sections 242 and 228 of the General Corporation Law of the State of Delaware.


IN WITNESS WHEREOF, said AVENTIS PASTEUR INC. has caused this certificate to be signed by Damian A. Braga, its President, and attested by Charles S. Montgomery, its Secretary this 10th day of January, 2005.

AVENTIS PASTEUR INC.



Damian A. Braga, President

ATTEST:

by 

Charles S. Montgomery, Secretary



sanofi aventis

Because health matters

Paris, January 10, 2005

***Aventis Pasteur, the vaccine division of the sanofi-aventis Group,
changes its name to sanofi pasteur***

Sanofi-aventis announced today the official change in the legal denomination of the Aventis Pasteur company, which will henceforth be named **sanofi pasteur**.

The General Meeting of Shareholders of Aventis Pasteur, held in December 2004, voted the change in name from **Aventis Pasteur** to **sanofi pasteur**. The Aventis Pasteur MSD joint venture, equally owned by Aventis Pasteur and Merck & Co. Inc., which markets vaccines in Europe, also changes its denomination to **Sanofi Pasteur MSD**.

The heritage of **sanofi pasteur** in the field of human vaccines is outstanding and has been handed down to us by major historical figures such as Louis Pasteur, Marcel Mérieux and Charles Mérieux as well as John Fitzgerald, the founder of Connaught Laboratories. All of them have marked the history of vaccinations.

Today **sanofi pasteur** proposes the largest range of vaccines, offering prevention against 20 bacterial and viral diseases.

Faithful to its history, and fortified by the commitment of the sanofi-aventis Group in the area of vaccines, **sanofi pasteur** will pursue its public health mission worldwide.

The vaccine division of the sanofi-aventis Group, **sanofi pasteur**, is one of the worldwide leaders in this field. It offers pediatric combination vaccines, influenza vaccines, polio vaccines, meningitis vaccines, adult boosters and a range of vaccines for travellers and endemic areas. In 2003, 1.4 billion vaccine doses were administered to more than 500 million people. Sales in 2003 reached 1.6 billion euros. The division has more than 8,500 employees in the world including 4,300 in France. Its Headquarters are located in Lyon, France.

About sanofi-aventis

Sanofi-aventis is the world's 3rd largest pharmaceutical company, ranking number 1 in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine, vaccines. Sanofi-aventis is listed in Paris (EURONEXT : SAN) and in New York (NYSE : SNY).

P
r
e
s
s
r
e
l
e
a
s
e



sanofi aventis

Because health matters

Forward Looking Statement

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expect," "anticipates," "believes," "intends," "estimates" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by Sanofi-aventis and Aventis, including those listed under "Forward-Looking Statements" and "Risk Factors" in sanofi-aventis's annual report on Form 20-F for the year ended December 31, 2003 and those listed under "Cautionary Statement Regarding Forward-Looking Statements" and "Risk Factors" in Aventis's annual report on Form 20-F for the year ended December 31, 2003. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

P
r
e
s
s
r
e
l
e
a
s
e

